On January 20, 2022, ImmPACT Bio USA Inc. closed the transaction. The company received $110,855,842.586 in a round of funding co-led by new investors, venBio LLC, Foresite Capital Management, LLC, and Decheng Capital LLC. The transaction also included participation from other new investor, Citadel Multi-Strategy Equities Master Fund Ltd., a fund managed by Citadel Advisors LLC, returning investors, OrbiMed Advisors LLC, Novartis Venture Funds, RM Global Partners LLC, Investment Arm, and Bukwang Pharmaceutical Co., Ltd. The company has raised around $129,000,000 in funding till date.

Yvonne Yamanaka of venBio LLC, Cindy Xiong of Foresite Capital Management, LLC, and Min Cui of Decheng Capital LLC will join the company's board of director as a part of the transaction. The company received funding pursuant to Regulation D from total 13 investors.